Related references
Note: Only part of the references are listed.Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
Rene Westhovens et al.
RHEUMATOLOGY (2021)
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Hyoun-Ah Kim et al.
BIODRUGS (2020)
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies
Sang Joon Lee et al.
BIODRUGS (2020)
A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Tae-Hwan Kim et al.
CLINICAL DRUG INVESTIGATION (2020)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
G. L. Goll et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Tomoo Nakagawa et al.
INTESTINAL RESEARCH (2019)
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2017)
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort
Anita Balint et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort
Lorant Gonczi et al.
INFLAMMATORY BOWEL DISEASES (2017)
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2017)
Interchangeability of Biosimilars: A European Perspective
Pekka Kurki et al.
BIODRUGS (2017)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry
Denis Choquette et al.
JOURNAL OF RHEUMATOLOGY (2015)
The history and fate of the gold standard
David S. Jones et al.
LANCET (2015)
Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a Canadian Multicenter Prospective Observational Registry
Carter Thorne et al.
ARTHRITIS CARE & RESEARCH (2014)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview
Su Golder et al.
PLOS MEDICINE (2011)
Share Paper
